Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports

Lydia Hahl-Häkkinen, Susanna Maria Rask, Anssi Solismaa, Sanna Ruuhonen, Esa Leinonen

Research output: Contribution to journalArticleScientific

1 Citation (Scopus)
14 Downloads (Pure)

Abstract

Background: Alcohol use disorder (AUD) is a significant co-morbidity in patients with schizophrenia. Clozapine offers some benefits in treating patients with refractory schizophrenia and AUD, but co-medicating with disulfiram is also common. Procedures: We report two cases where co-medicating with disulfiram led to a significant increase in clozapine serum levels. Findings: Clozapine serum levels decreased to one-third in Patient 1 when disulfiram was discontinued and started to increase again when disulfiram was reintroduced. Patient 2 developed toxic serum levels of clozapine during disulfiram treatment combined with heavy coffee drinking and symptoms reminiscent of neuroleptic malignant syndrome. Conclusions: Clozapine and disulfiram are both metabolized by cytochrome P450 CYP1A2 and clinically relevant interaction through this shared pathway is possible.

Original languageEnglish
Pages (from-to)229-233
Number of pages5
JournalJOURNAL OF PSYCHOPHARMACOLOGY
Volume37
Issue number2
DOIs
Publication statusPublished - 2023
Publication typeB1 Journal article

Keywords

  • Alcohol use disorder
  • clozapine
  • disulfiram
  • interaction
  • toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports'. Together they form a unique fingerprint.

Cite this